Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are widely used in anti-tumor therapy for non-small cell lung cancer (NSCLC) [114]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.